Mepolizumab Dosage

Medically reviewed by Drugs.com. Last updated on Jan 14, 2025.

Usual Adult Dose for Asthma - Maintenance

100 mg subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen.

Use: Add-on maintenance treatment for severe asthma with an eosinophilic phenotype

Usual Adult Dose for Wegener's Granulomatosis

300 mg (as 3 separate 100 mg injections) subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen as 3 separate 100 mg injections at least 5 cm (approximately 2 inches) apart if more than 1 injection is administered at the same site.

Use: For eosinophilic granulomatosis with polyangiitis (EGPA)

Usual Adult Dose for Sinusitis

100 mg subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen

Use: Adult patients with chronic rhinosinusitis with nasal polyps

Usual Adult Dose for Nasal Polyps

100 mg subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen

Use: Adult patients with chronic rhinosinusitis with nasal polyps

Usual Adult Dose for Rhinitis

100 mg subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen

Use: Adult patients with chronic rhinosinusitis with nasal polyps

Usual Adult Dose for Hypereosinophilic Syndrome

300 mg (as 3 separate 100 mg injections) subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen as 3 separate 100 mg injections at least 5 cm (approximately 2 inches) apart.

Use: Adult patients with hypereosinophilic syndrome

Usual Pediatric Dose for Asthma - Maintenance

6 to 12 years:
40 mg subcutaneously every 4 weeks

12 years or older:
100 mg subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen.

Use: Add-on maintenance therapy for severe asthma with an eosinophilic phenotype in children 6 years and older

Usual Pediatric Dose for Hypereosinophilic Syndrome

300 mg (as 3 separate 100 mg injections) subcutaneously every 4 weeks

Comments:

• This drug should be administered in the upper arm, thigh, or abdomen as 3 separate 100 mg injections at least 5 cm (approximately 2 inches) apart.

Use: Patients 12 years and older with hypereosinophilic syndrome without an identifiable non-hematologic secondary cause

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

US FDA requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients

• Asthma: Safety and efficacy have not been established in patients younger than 6 years old.
• Rhinosinusitis with nasal polyps and EGPA: Safety and efficacy have not been established in patients under 18 years old.
• Hypereosinophilic syndrome: Safety and efficacy have not been established in patients under 12 years old.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug should be reconstituted and administered by a health care provider.
• Discard if cloudy, milky, or particulate matter remains in solution after reconstitution.
• This drug is for subcutaneous use only. Administration in upper arm, thigh, or abdomen is preferred.

Storage requirements:

• Lyophilized powder: Protect from light; do not freeze.
• Reconstituted solution: Do not freeze; discard if not used within 6 to 8 hours of reconstitution.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

General:

• This drug should not be used to treat other eosinophilic conditions, acute asthma, bronchospasm, or status asthmaticus.
• Avoid decreasing or discontinuing corticosteroids during initiation of this drug.
• This drug may interfere with helminth infections.
• Hypersensitivity reactions may occur up to days after administration.
• This drug should be prescribed by healthcare professionals experienced in the diagnosis and treatment of severe asthma.

Monitoring:

• Signs and symptoms of uncontrolled or worsening asthma
• Signs and symptoms of an allergic reaction (e.g., facial swelling, rash, hypotension, hives)

Patient advice:

• Read the Patient Information and Instructions for Use.
• Warn patients to avoid interruptions or abrupt discontinuation of corticosteroids.
• Instruct patients to notify their healthcare provider upon signs and symptoms of worsening asthma or allergic reaction.
• Patients should be advised to speak to their healthcare provider if pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

• How long does it take for Nucala to work?
• Can Nucala cause weight gain?
• Can Nucala be self-administered? How is it injected?
• How does Nucala (mepolizumab) work? What is the MOA?
• What is Nucala (mepolizumab) used for and how is it given?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer